0001493152-23-028716.txt : 20230814 0001493152-23-028716.hdr.sgml : 20230814 20230814190730 ACCESSION NUMBER: 0001493152-23-028716 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230811 FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Morris Jeffrey Allen CENTRAL INDEX KEY: 0001959175 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36457 FILM NUMBER: 231172717 MAIL ADDRESS: STREET 1: 1729 TRIANGLE PARK DR. CITY: MARYVILLE STATE: TN ZIP: 37801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 S. GAY STREET STREET 2: SUITE 1610 CITY: KNOXVILLE STATE: TN ZIP: 37929 BUSINESS PHONE: (866) 594-5999 MAIL ADDRESS: STREET 1: 800 S. GAY STREET STREET 2: SUITE 1610 CITY: KNOXVILLE STATE: TN ZIP: 37929 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 4 1 ownership.xml X0508 4 2023-08-11 0 0000315545 PROVECTUS BIOPHARMACEUTICALS, INC. PVCT 0001959175 Morris Jeffrey Allen 1729 TRIANGLE PARK DRIVE MARYVILLE TN 37801 0 0 1 0 0 Common Stock 12000000 D Common Stock 6500000 I By IRA Series D-1 Convertible Preferred Stock 3995747 D 8% Secured Convertible Promissory Note 2.862 2023-08-11 4 A 0 700000 0 A 2023-08-11 2024-08-11 Series D-1 Convertible Preferred Stock 244584 244584 D The reporting person has sole voting and dispositive power over 12,000,000 shares of Common Stock. The reporting person has sole voting and dispositive power over 6,500,000 shares of Common Stock owned through an IRA retirement plan. The reporting person has sole voting and dispositive power over 3,995,747 shares of Series D-1 Convertible Preferred Stock, convertible into 39,957,470 shares of Common Stock. The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2022 Financing. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). /s/ Jeffrey Allen Morris 2023-08-14